title: Lack of association of the TP53BP1 Glu353Asp polymorphism with risk of cancer: a systematic review and meta-analysis.
abstract: OBJECTIVE
  The TP53BP1 gene may be involved in the development of cancer through disrupting DNA repair. However, studies investigating the relationship between TP53BP1 Glu353Asp (rs560191) polymorphism and cancer yielded contradictory and inconclusive outcomes. In order to realize these ambiguous findings, a meta-analysis was performed to assess the association between the TP53BP1 Glu353Asp (rs560191) polymorphism and susceptibility to cancer.
  
  
  METHODS
  We conducted a search of all English reports on studies for the association between the TP53BP1 Asp353Glu (rs560191) polymorphism and susceptibility to cancer using Medline, the Cochrane Library, EMbase, Web of Science, Google (scholar), and all Chinese reports were identified manually and on-line using CBMDisc, Chongqing VIP database, and CNKI database. The strict selection criteria and exclusion criteria were determined, and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. The fixed or random effect model was selected based on the heterogeneity test among studies. Publication bias was estimated using funnel plots and Egger's regression test.
  
  
  RESULTS
  A total of seven studies were included in the meta-analysis including 3,213 cases and 3,849 controls. The results indicated that the Glu353Asp (rs560191) polymorphism in TP53BP1 gene had no association with cancer risk for all genetic models. In the subgroup analysis, the results suggested that Glu353Asp polymorphism was not associated with the risk of cancer according to ethnicity, cancer type, genotyping method, adjusted with control or not, HWE and quality score.
  
  
  CONCLUSIONS
  This meta-analysis suggested that the Glu353Asp (rs560191) polymorphism in TP53BP1 gene was not associated with risk of cancer.
authors.affiliation: Department of Ophthalmology, The First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China; Department of Epidemiology, School of Public Health, China Medical University, Shenyang City, Liaoning Province, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Anesthesiology, Fengtian Hospital, Shenyang Medical College, Shenyang City, Liaoning Province, China.
authors.forename: Jinghua
authors.initials: J
authors.lastname: Jiao
authors.affiliation: Department of Development and Planning office, China Medical University, Shenyang City, Liaoning Province, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of General Surgery, the Fourth People's Hospital of Shenyang, Shenyang City, Liaoning Province, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Department of Ophthalmology, The First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.
authors.forename: Jingyang
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Epidemiology, School of Public Health, China Medical University, Shenyang City, Liaoning Province, China.
authors.forename: Desheng
authors.initials: D
authors.lastname: Huang
mesh_terms: D000483:Alleles; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D015870:Gene Expression; D005787:Gene Frequency; D005838:Genotype; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000473:pathology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012306:Risk; D000071857:Tumor Suppressor p53-Binding Protein 1
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; C498301:TP53BP1 protein, human; D000071857:Tumor Suppressor p53-Binding Protein 1